Goldstein Allan L's Form 4 filing
Regenerx Biopharmaceuticals Inc (RGRX) · filed Jul 6, 2021
- Accession no.
- 0000914190-21-000192
- Filed
- Jul 6, 2021, 4:34 PM ET
- Trade date
- Jun 30, 2021
- Filing delay
- 6 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction and 2 derivative transactions. Open-market purchases total $25.0K. It was filed 6 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Goldstein Allan LCIK 0000905390 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 30, 2021 | Common Stock | PPurchaseAcquired | +125,000 | $0.20 | +$25,000 | 1,637,793 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 30, 2021 | Common Stock | PPurchaseAcquired | +93,750 | $0.00 | $0 | 93,750 | Direct | |
| Jun 30, 2021 | Common Stock | PPurchaseAcquired | +93,750 | $0.00 | $0 | 93,750 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.